Literature DB >> 15380279

Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

Douglas J Biedenbach1, Gary J Moet, Ronald N Jones.   

Abstract

The empiric treatment of patients with bloodstream infections (BSI) has become more complicated in an era of increasing antimicrobial resistance. The SENTRY Antimicrobial Surveillance Program has monitored BSI from patients in medical centers worldwide since 1997. During 1997-2002, a total of 81,213 BSI pathogens from North America, Latin America, and Europe were tested for antimicrobial susceptibility. S. aureus, E. coli, and coagulase-negative staphylococci were the three most common BSI pathogens in all three regions each year. Prevalence variability was noted in regions for some species, including higher rates of isolation of E. coli in Europe, Enterococcus spp. in North America, and Gram-negative enteric and nonenteric species in Latin America. Patient age analysis showed the most common BSI pathogen among neonates was coagulase-negative staphylococci and among elderly patients, E. coli. Resistance among BSI pathogens was much more prevalent in nosocomial infections and in patients in intensive care units (ICUs); age differences were also noted. Geographically, oxacillin-resistant S. aureus (39.1%, 2002) and vancomycin-resistant enterococci (17.7%, 2002) were highest in North America, and extended-spectrum beta-lactamase-producing Klebsiella spp. (35.8-46.7%) and multidrug-resistant P. aeruginosa (18.7%, 2002) were highest in Latin America. Activity of commonly used antimicrobial agents remained relatively stable in North America, except in the case of vancomycin-resistant enterococci (20% decline between 1997 and 2002). An epidemiologic investigation of oxacillin-resistant S. aureus in North America identified 10 significant clones (ribotypes) and the common resistance patterns associated with them. Surveillance of BSI pathogens is needed to determine trends of resistance and provide useful information regarding patient risk factors and geographic differences.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380279     DOI: 10.1016/j.diagmicrobio.2004.05.003

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  98 in total

1.  MRSA screening: is it really necessary in primary care?

Authors:  Tarique Khan; Amanda Beaumont
Journal:  Br J Gen Pract       Date:  2010-07       Impact factor: 5.386

Review 2.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

3.  In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

Authors:  A Walkty; M DeCorby; P R S Lagacé-Wiens; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

Review 4.  Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.

Authors:  C Andrew DeRyke; Su Young Lee; Joseph L Kuti; David P Nicolau
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.

Authors:  Eun Jeong Yoon; Yeong Woo Jo; Sung Hak Choi; Tae Ho Lee; Jae Keol Rhee; Moohi Yoo; Mi Ja Shim; Eung Chil Choi
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections.

Authors:  C Hal Jones; Margareta Tuckman; Anita Y M Howe; Mark Orlowski; Stanley Mullen; Karen Chan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

7.  A multiplex real-time PCR assay for rapid detection and differentiation of 25 bacterial and fungal pathogens from whole blood samples.

Authors:  Lutz Eric Lehmann; Klaus-Peter Hunfeld; Thomas Emrich; Gerd Haberhausen; Heimo Wissing; Andreas Hoeft; Frank Stüber
Journal:  Med Microbiol Immunol       Date:  2007-11-16       Impact factor: 3.402

Review 8.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

9.  Sources of systematic errors in the epidemiology of vancomycin-resistant enterococci.

Authors:  N T Mutters; U Frank
Journal:  Infection       Date:  2013-02-06       Impact factor: 3.553

10.  Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy.

Authors:  Graeme N Forrest; Mary-Claire Roghmann; Latoya S Toombs; Jennifer K Johnson; Elizabeth Weekes; Durry P Lincalis; Richard A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.